Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05263453 | HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation | unknown | Phase 2 | 104 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05823246 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 2 | 66 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT04703426 |
| Sargramostim (GM-CSF) + PD-1 |
| withdrawn |
| Phase 2 |
| 0 |
| Dana-Farber Cancer InstituteOTHER |
| 0 |
| May 22, 2023 |
| clinicaltrials |
| NCT01502293 | Trial of pIL-12 Electroporation Malignant Melanoma(IL-12MEL) | completed | Phase 2 | 51 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03171064 | Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment(Sportivumab) | completed | Phase 2 | 39 | University Hospital HeidelbergOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05854589 | Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number. | unknown | Phase 2 | 20 | Rafik BatroussyOTHER | 0 | May 11, 2023 | clinicaltrials |
| NCT05723432 | KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma | unknown | Phase 1 / Phase 2 | 84 | Shanghai Kanda Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05827770 | The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma | unknown | Phase 2 | 20 | Yong ChenOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT01995344 | TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment(METILDA) | terminated | Phase 2 | 2 | The Christie NHS Foundation TrustOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05234437 | A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma | terminated | Phase 2 | 1 | QBiotics Group LimitedINDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | terminated | Phase 2 | 47 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04834973 | A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma | terminated | Phase 1 / Phase 2 | 3 | QBiotics Group LimitedINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05496192 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 14, 2023 | clinicaltrials |
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | unknown | Phase 2 | 52 | Suthee RapisuwonOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT00667953 | Study of Temzolomide and Gleevec in Advanced Melanoma | terminated | Phase 1 / Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03132675 | Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment(Keynote-695) | unknown | Phase 2 | 143 | OncoSec Medical IncorporatedINDUSTRY | 5 | Mar 27, 2023 | clinicaltrials |
| NCT02570308 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | completed | Phase 1 / Phase 2 | 146 | Immunocore LtdINDUSTRY | 5 | Mar 21, 2023 | clinicaltrials |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05767879 | (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | unknown | Phase 2 | 28 | Leiden University Medical CenterOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03534635 | Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) | unknown | Phase 2 | 30 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05664139 | Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Feb 8, 2023 | clinicaltrials |
| NCT03166397 | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | unknown | Phase 2 | 30 | Sheba Medical CenterOTHER_GOV | 1 | Jan 26, 2023 | clinicaltrials |
| NCT01993719 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02821182 | A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. | completed | Phase 2 | 20 | University Hospital, GhentOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02731729 | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | completed | Phase 2 | 20 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT02052193 | Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study | terminated | Phase 2 | 8 | University Hospital TuebingenOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT03241186 | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | active not recruiting | Phase 2 | 36 | Robert R. McWilliams, MDOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04633902 | Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | unknown | Phase 2 | 41 | California Pacific Medical Center Research InstituteOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05077280 | A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma | unknown | Phase 2 | 40 | California Pacific Medical Center Research InstituteOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02414750 | Vemurafenib Plus Cobimetinib in Metastatic Melanoma(REPOSIT) | terminated | Phase 2 | 78 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT05051865 | To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma | unknown | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT00945269 | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 3 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT02038348 | Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study | completed | Phase 2 | 5 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01807182 | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05406466 | Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02115139 | GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases(GRAY-B) | completed | Phase 2 | 58 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02036086 | Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | unknown | Phase 2 | 24 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT00518206 | Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | completed | Phase 2 | 46 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT00520299 | Study of ADI-PEG 20 in Patients With Advanced Melanoma | completed | Phase 1 / Phase 2 | 31 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03396952 | Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | completed | Phase 2 | 27 | University of California, San FranciscoOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT00199901 | Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | completed | Phase 2 | 111 | Ludwig Institute for Cancer ResearchOTHER | 3 | Oct 12, 2022 | clinicaltrials |
| NCT00679289 | Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | completed | Phase 2 | 36 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04172454 | Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2023source: clinicaltrials